Alzheimer's Research & Therapy | Volume 2 Issue 3

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

cover

	Volume 2 Issue 3
	Comment
	Commentary Increasing incidence of dementia in the oldest old: evidence and implications Bryan D James, Julie A Schneider Alzheimer's Research & Therapy 2010, 2:9 (13 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The implications of a study suggesting an exponential rise in dementia in persons 90 years and older are discussed and compared to other studies reporting a slowing incidence.
	Commentary The involvement of cell cycle events in the pathogenesis of Alzheimer's disease Karl Herrup Alzheimer's Research & Therapy 2010, 2:13 (20 May 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Cell cycle events in Alzheimer’s disease and other late-onset neurodegenerative diseases are not fully understood, but elucidating these complex relationships may pave the way to developing new therapeutic interventions.
	Commentary Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? Martin R Farlow Alzheimers Res Ther 2010, 2:15 (8 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Variations in the ApoE genotype may affect the rate of disease progression and response to therapy in Alzheimer’s disease, suggesting it should be included as a covariate for future trials.
	Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
	Viewpoint Con: Can biomarkers be gold standards in Alzheimer's disease? Kenneth Rockwood Alzheimer's Research & Therapy 2010, 2:16 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Rockwood argues that we should employ a number of clinical measures, such as neuropsychological tests and clinical interviews, rather than relying solely on biomarkers to predict Alzheimer’s disease outcome.
	Viewpoint Pro: Can biomarkers be gold standards in Alzheimer's disease? Reisa Sperling, Keith Johnson Alzheimer's Research & Therapy 2010, 2:17 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Sperling and Johnson argue that biomarkers can approximate the diagnostic accuracy of autopsy in Alzheimer’s patients and may be able to track progression of the disease prior to significant cognitive impairment.
	Correction Correction: Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:14 (18 May 2010) Full text \| PDF \| PubMed
	Research
	Research Vascular health, diabetes, APOE and dementia: the Aging, Demographics, and Memory Study David J Llewellyn, Iain A Lang, Fiona E Matthews, Brenda L Plassman, Mary AM Rogers, Lewis B Morgenstern, Gwenith G Fisher, Mohammed U Kabeto, Kenneth M Langa Alzheimer's Research & Therapy 2010, 2:19 (24 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Stroke and the APOE epsilon4 allele are strongly associated with dementia, and antihypertensive medications may inform the development of more effective interventions and treatments.
	Research Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease Erik Stomrud, Maria Björkqvist, Sabina Janciauskiene, Lennart Minthon, Oskar Hansson Alzheimer's Research & Therapy 2010, 2:20 (24 June 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Matrix metalloproteinases are elevated in patients with Alzheimer’s disease (AD) and might be associated with early pathogenesis of AD in individuals who have not developed overt cognitive dysfunction.